MRI Scoring System Shows Promise for Telling Benign From Malignant Breast Lesions

One of the most stubborn diagnostic challenges in breast imaging has long been the non-mass enhancement lesion, a finding that on magnetic resonance imaging does not present as a discrete lump but instead as an area of tissue that lights up with contrast in ways that can be maddeningly ambiguous. Unlike a clear mass, which radiologists can measure, characterize, and often classify with reasonable confidence, non-mass enhancement spreads across breast tissue in patterns that overlap heavily between benign conditions such as inflammation, fibrocystic change, and radiation effects, and malignant processes including ductal carcinoma in situ and invasive cancer. A new study published in BMC Medical Imaging now offers a structured way out of that uncertainty, presenting a combined clinical and radiological scoring system built from routine breast MRI features that could help clinicians decide which of these lesions warrant aggressive workup and which can be monitored more conservatively.

The research, led by Yun He and Ping Li along with colleagues at Zhejiang Cancer Hospital in Hangzhou, China, enrolled 199 women who had undergone breast MRI for evaluation of non-mass enhancement lesions. Of these patients, 76 ultimately proved to have benign lesions while 123 had malignant disease confirmed by pathology. The goal was straightforward but ambitious: identify which clinical and imaging characteristics genuinely separate benign from malignant non-mass enhancement, and then distill those characteristics into a scoring system that a radiologist could apply in everyday practice without needing specialized software or advanced computational tools.

The methodological approach was rigorous and systematic. The researchers first used the Mann-Whitney U test to compare the ages of women in the benign and malignant groups, since age is one of the most fundamental risk factors in breast cancer. They then applied nonparametric statistical tests to examine differences between the two groups across a comprehensive battery of imaging variables, including the type of glandular tissue in the breast, the degree of background parenchymal enhancement, which reflects how much normal breast tissue takes up contrast on its own, the signal characteristics of lesions on T1-weighted, T2-weighted, and diffusion-weighted imaging, the morphological distribution of the enhancement, the enhancement patterns of the lesions themselves, the early enhancement rate, and the shape of the time-intensity curve, a dynamic measure of how quickly contrast flows into and out of the lesion over the course of the scan.

The univariate analysis revealed significant differences between benign and malignant lesions across several of these dimensions. Age mattered, as expected. The signal patterns observed on T1-weighted, T2-weighted, and diffusion-weighted imaging all showed discriminatory power, as did the morphological distribution of the enhancement, the enhancement pattern of the lesion, and the early fast enhancement rate. These findings align with established radiological principles: malignant tissue tends to have different water content and cellularity than benign tissue, which alters its appearance on different MRI sequences, and malignant lesions typically show more aggressive and disordered vascularization, producing faster and more intense contrast uptake.

To move from association to prediction, the team fed the statistically significant univariate variables into multivariable logistic regression, a technique that determines which factors remain independently predictive when all others are accounted for. Five features emerged as independent predictors of malignancy in non-mass enhancement lesions: age greater than 40 years, diffusion restriction on diffusion-weighted imaging, segmental distribution of the lesion, diffuse distribution of the lesion, and an early fast enhancement rate. Each of these predictors carried an odds ratio quantifying how strongly it associated with malignancy, and the researchers used the magnitude of these odds ratios as the basis for assigning points in their scoring system. This approach gives the score an intuitive logic, with features that carry greater statistical weight contributing more to a patient’s total score.

The performance of the resulting score was encouraging, particularly on one critical dimension. Measured by the area under the receiver operating characteristic curve, a standard metric of diagnostic discrimination where 0.5 represents chance and 1.0 represents perfection, the scoring system achieved an AUC of 0.843. More strikingly, the system demonstrated a specificity of 90.79 percent, meaning that when the score indicates a lesion is benign, that assessment is very likely correct. The sensitivity was moderate at 62.6 percent, indicating that the score catches a meaningful but incomplete proportion of malignant lesions. In practical terms, this profile suggests the tool may be most valuable for identifying patients whose non-mass enhancement lesions are very likely benign, potentially sparing them unnecessary biopsy, while ensuring that unclear cases still proceed to tissue sampling.

The clinical significance of this work becomes clearer when considering the wider context of breast MRI screening. Breast MRI is increasingly used in high-risk screening programs and in the evaluation of patients with newly diagnosed cancer, and non-mass enhancement is a common finding in these settings. Because such lesions cannot be reliably characterized by ultrasound or mammography, radiologists often face a dilemma: recommend biopsy with its associated costs, anxiety, and procedural risks, or recommend follow-up imaging with the possibility of delaying a cancer diagnosis. A validated scoring system built from features already visible on a standard clinical MRI, requiring no additional imaging sequences or expensive post-processing, offers a practical middle path that could reduce unnecessary interventions without compromising safety.

The technical underpinnings of the score also merit attention. Diffusion-weighted imaging reflects the random motion of water molecules within tissue, and restriction of that motion is a hallmark of highly cellular tissue, which is characteristic of many tumors. Segmental distribution, in which enhancement follows the branching architecture of a ductal system, and diffuse distribution are morphological patterns long recognized in the Breast Imaging Reporting and Data System lexicon as suspicious, while the early enhancement rate captures the kinetic behavior of contrast uptake that reflects tumor angiogenesis. By combining these imaging features with the simple clinical variable of patient age, the scoring system leverages complementary streams of information in a way that mirrors how experienced radiologists reason through difficult cases, but in a standardized and reproducible format.

The authors are careful to frame their findings as a foundation rather than a finished clinical tool. They note that the scoring system has good discriminative performance with high specificity and moderate sensitivity, and that with further refinement and larger datasets it may serve as a useful diagnostic aid in clinical practice. The single-center design and the moderate sample size of 199 patients mean that external validation in independent, more diverse populations will be essential before widespread adoption. Future work could also explore combining the score with emerging computational approaches, including machine learning models trained on radiomic features, potentially pushing sensitivity higher while preserving the impressive specificity achieved here.

Nevertheless, the study represents a meaningful step toward more rational, evidence-based management of one of breast radiology’s most persistent diagnostic gray zones. As MRI use in breast care continues to expand worldwide, tools that convert complex imaging findings into clear, actionable risk estimates will only grow in importance. For the many women each year who receive an ambiguous non-mass enhancement finding on breast MRI, a simple score that reliably separates the benign from the malignant could translate into fewer unnecessary biopsies, faster diagnoses for those who need treatment, and a meaningful reduction in the anxiety that accompanies uncertainty. The work by He, Li, and their colleagues demonstrates that the raw ingredients for such a tool already exist within a standard clinical MRI examination, waiting only to be systematically assembled and validated.

Subject of Research: Development of a clinical-radiological MRI-based scoring system to predict benignity and malignancy of non-mass enhancement breast lesions

Article Title: A clinical-radiological MRI-based combined scoring system for predicting benignity and malignancy of non-mass enhancement breast lesions

Article References: He, Y., Li, P., Nan, S., Dai, G., Wang, X., Wei, Y., & Deng, X. (2026). A clinical-radiological MRI-based combined scoring system for predicting benignity and malignancy of non-mass enhancement breast lesions. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02830-1

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02830-1

Keywords: breast cancer, breast MRI, non-mass enhancement, scoring system, diffusion-weighted imaging, logistic regression, diagnostic specificity, BMC Medical Imaging, radiology, lesion characterization, dynamic contrast-enhanced MRI, clinical prediction